NCT00816504View on ClinicalTrials.gov

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

Galactose

Oral galactose, 0.2 g/kg/dose twice daily for 28 days

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

lead

Northwell Health

OTHER

NCT00816504 - Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 | Biotech Hunter | Biotech Hunter